In the phase ARROW trial, pralsetinib demonstrated a promising ORR of 60% and DCR of 93% in RET-rearranged NSCLCs.[10] Most patients had a duration of response ≥ of 6 months.[9] So far, we have not found report about LINCO1264-RET and SEMA5A-RET co-occurring with the common RET was sensitive to pralsetinib or LOXO 292 (selpercatinib) in the NSCLC. Here, RET is linked to non-small cell lung carcinoma.